Sichenzia Ross Friedman Ference LLP Advises Cell Source, Inc. on $500,000 PIPE Financing
New York, NY – April 1, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm represented Cell Source, Inc. (OTCQB: CLCS), a biomedical technology company focused on developing cell therapy treatments, on an offering pursuant to which Cell Source issued and sold two promissory notes in the aggregate amount of $500,000 and two Warrants to purchase common stock to two accredited investors.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Gregory Sichenzia and Associate Jay Yamamoto.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
- Sichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering - April 10, 2019
- FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks - April 4, 2019